Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of “Hold” by Brokerages

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $55.50.

A number of equities analysts have commented on TVRD shares. Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. BTIG Research reduced their price objective on Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, October 13th. Piper Sandler lowered Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Finally, Raymond James Financial cut shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th.

Tvardi Therapeutics Price Performance

TVRD stock opened at $4.55 on Friday. The firm has a market cap of $42.68 million, a price-to-earnings ratio of -0.47 and a beta of 0.09. Tvardi Therapeutics has a 1-year low of $3.74 and a 1-year high of $43.65. The firm has a fifty day moving average price of $4.12 and a two-hundred day moving average price of $18.08.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24.

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TVRD. Geode Capital Management LLC bought a new position in Tvardi Therapeutics in the 2nd quarter worth approximately $2,617,000. JPMorgan Chase & Co. bought a new position in shares of Tvardi Therapeutics in the second quarter worth $39,000. New York State Common Retirement Fund acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at $92,000. Marshall Wace LLP bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at about $583,000. Finally, Slate Path Capital LP bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at about $16,427,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.